ADVERTISING ANALYSIS REVIEW

Source: Advertising Analysis Report, July 2004

Top 1 Advertised Drug Classes (\$ Millions) January—July 2004

| Cholesterol Reducers | | \$4.774 (+23%) |
|---------------------------------|----------------|----------------|
| COX-2 Inhibitors | | \$4.432 (+4%) |
| Antidepressants | | \$3.728 (+40%) |
| Angiotensin II Antagonists | | \$3.681 (-14%) |
| Ulcer Therapy | \$3.326 (+24%) | |
| Antibiotics | \$2.452 (+85%) | |
| Anti-asthmatics/Bronchodilators | \$2.293 (-21%) | |
| ACE Inhibitors | \$2.050 (+19%) | |
| Diabetes Diagnosis &Therapy | \$1.518 (-) | |
| Vaccines | \$1.227 (+73%) | |

Top Advertised Products January—July 2004

| Crestor | | \$1,948,000 (-6%) | |
|---------------|---------------------|--|--|
| Vioxx | \$1,638,000 (-) | | |
| Celebrex | \$1,418,000 (+17% | (6) | |
| Bextra | \$1,376,000 (-1%) | | |
| Lipitor | \$1,369,000 (-3%) | | |
| Effexor XR | \$1,329,000 (+4%) | | |
| Altace | \$1,111,000 (+27%) | | |
| Wellbutrin SR | \$1,025,000 (+999%) | | |
| Ezetrol | \$1,005,000 (+999%) | To find out more about these figures, contact your | |
| Advair | \$985,000 (+25%) | STA representative. | |
| | | John Donnet: (514) 695-8393, ext. 227 Carlo Viola: (905) 564-7700, ext. 201 | |